Search the site

Our Locations

At The Kids Research Institute Australia, we have a dedicated and diverse team of over 1,000 staff, students and honorary researchers.

Research

REACH: study protocol of a randomised trial of rehabilitation very early in congenital hemiplegia

Congenital hemiplegia is the most common form of cerebral palsy (CP). Children with unilateral CP show signs of upper limb asymmetry by 8 months corrected age (ca) but are frequently not referred to therapy until after 12 months ca. This study compares the efficacy of infant-friendly modified constraint-induced movement therapy (Baby mCIMT) to infant friendly bimanual therapy (Baby BIM) on upper limb, cognitive and neuroplasticity outcomes in a multisite randomised comparison trial.

News & Events

Birth Rates Rise After Baby Bonus Payments

Fertility rates increased following the introduction of the Federal government's "Baby Bonus" payments.

Workplace & corporate fundraising

Get your workplace and colleagues involved

People

Katrina Allen

Strategic Partnerships Manager

News & Events

Vaccination Q&A with Dr Chris Blyth

Immunisation plays an important role in preventing disease within our community. Watch Dr Chris Blyth answer some commonly asked questions about vaccines.

News & Events

Young Minds Matter overview

Young Minds Matter was funded by the Australian Government Department of Health. The survey was conducted at The University of Western Australia...

News & Events

Video: How to respond if your child is being bullied

In this video, Professor Donna Cross from the Telethon Kids Institute provides some practical advice on how to respond if your child is being bullied.

News & Events

Video: Top 6 ways to get your kids to eat their vegies

Nutritionist Dr Roslyn Giglia from The Kids Research Institute Australia shares her top 6 ways to get your kids to eat their vegies.

Research

Piperaquine Pharmacokinetic and Pharmacodynamic Profiles in Healthy Volunteers of Papua New Guinea after Administration of Three-Monthly Doses of Dihydroartemisinin-Piperaquine

Mass drug administration (MDA) with monthly dihydroartemisinin-piperaquine (DHA-PQP) appears useful in malaria control and elimination strategies. Determining the relationship between consecutive piperaquine phosphate (PQP) exposure and its impact on QT interval prolongation is a key safety consideration for MDA campaigns.